Larkspur Biosciences to Present New Preclinical Research on Lead Development Program Candidate, a First-in-Class PIP4K2C Protein Degrader, at AACR 2024
28. März 2024 08:00 ET
|
Larkspur Biosciences, Inc.
Larkspur Biosciences to Present New Preclinical Research on Lead Development Program Candidate, a First-in-Class PIP4K2C Protein Degrader, at AACR 2024
Larkspur Biosciences Announces CEO Catherine Sabatos-Peyton to Participate in Upcoming Biotech Events
14. Dezember 2023 08:00 ET
|
Larkspur Biosciences, Inc.
WATERTOWN, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Larkspur Biosciences, a company pioneering a new wave in cancer therapy that stops immune evasion from where it starts in the tumor, announced...
Larkspur Biosciences to Present New Mechanistic Data on the Role of Pin1 in Modulating the Fibroblast – Cancer Axis at SITC 2023
25. Oktober 2023 08:00 ET
|
Larkspur Biosciences, Inc.
WATERTOWN, Mass., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Larkspur Biosciences, a biotechnology company building precision therapies to outsmart cancer, announced that data supporting development of a...
Larkspur Biosciences Announces First-in-Class Program Targeting Novel B Cell Checkpoint
26. Juni 2023 07:00 ET
|
Larkspur Biosciences, Inc.
Research foundational to Larkspur’s newly disclosed TIM-1 program published by founder Vijay K. Kuchroo in Nature WATERTOWN, Mass., June 26, 2023 (GLOBE NEWSWIRE) -- Larkspur Biosciences revealed...
Larkspur Biosciences to Participate in the 2023 BIO International Convention
30. Mai 2023 08:00 ET
|
Larkspur Biosciences, Inc.
WATERTOWN, Mass., May 30, 2023 (GLOBE NEWSWIRE) -- Larkspur Biosciences, a biotechnology company building the next precision immunotherapies to outsmart cancer, announced that they will be...
Larkspur Biosciences Launches with $35.5 Million in Financing to Build the Next Precision Immunotherapies to Outsmart Cancer
23. Mai 2023 05:30 ET
|
Larkspur Biosciences, Inc.
Addressing the Key Bottlenecks in the Tumor Microenvironment That Allow a Tumor to Subvert the Immune System Financing Co-led by Polaris Innovation Fund, 3E Bioventures Capital, and Takeda...